Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

276
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
276
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

382
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
382
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

354
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
354
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

496
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
496
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Venous Return01:04

Venous Return

12.6K
The circulatory system plays a crucial role in ensuring the optimal functioning of the human body. One of its critical components is venous return - the process that completes the blood circulation cycle. This article will delve into the concept of venous return, how it works, and its significance to our health.
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
12.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients.

Medicina intensiva·2021
Same author

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients.

Medicina intensiva·2021
Same author

Associations of thrombocytopenia, transaminase elevations, and transfusion with laboratory coagulation tests in women with preeclampsia: a cross-sectional study.

International journal of obstetric anesthesia·2021
Same author

Lemierre syndrome - treat with antibiotics, anticoagulants or both?

Journal of internal medicine·2020
Same author

Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials.

Journal of thrombosis and haemostasis : JTH·2017

Related Experiment Video

Updated: Feb 15, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.3K

Anticoagulation in venous thrombosis

S Schulman1

  • 1Department of Internal Medicine, Karolinska Hospital, Stockholm, Sweden.

Journal of the Royal Society of Medicine
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Current deep vein thrombosis treatment guidelines recommend weight-based heparin dosing, preferably via twice-daily subcutaneous injections. Extended oral anticoagulation for six months is now advised, with low-molecular-weight heparin as a safe alternative for prophylaxis.

More Related Videos

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

16.4K
Electrolytic Inferior Vena Cava Model EIM of Venous Thrombosis
06:03

Electrolytic Inferior Vena Cava Model EIM of Venous Thrombosis

Published on: July 12, 2011

17.8K

Related Experiment Videos

Last Updated: Feb 15, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.3K
Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

16.4K
Electrolytic Inferior Vena Cava Model EIM of Venous Thrombosis
06:03

Electrolytic Inferior Vena Cava Model EIM of Venous Thrombosis

Published on: July 12, 2011

17.8K

Area of Science:

  • Cardiology
  • Hematology
  • Vascular Medicine

Background:

  • Deep vein thrombosis (DVT) remains a significant clinical challenge.
  • Optimal anticoagulation strategies are crucial for patient outcomes.
  • Evolving research necessitates updated treatment protocols for DVT.

Purpose of the Study:

  • To review and synthesize major studies on deep vein thrombosis treatment.
  • To provide evidence-based recommendations for current DVT management.
  • To highlight advancements in anticoagulation therapies for DVT.

Main Methods:

  • Comprehensive literature review of major studies on DVT treatment.
  • Analysis of current evidence regarding heparin and oral anticoagulation.
  • Evaluation of safety and efficacy data for different anticoagulation regimens.

Main Results:

  • Heparin dosing should be weight-based and administered subcutaneously twice daily.
  • Low-molecular-weight heparins offer a fixed-dose, once-daily alternative without monitoring.
  • Concomitant oral anticoagulation, targeting an international normalized ratio of 2.0-3.0, is recommended.
  • Treatment duration should extend to six months for most patients.
  • Low-molecular-weight heparin is effective and safe for secondary prophylaxis in patients with contraindications.

Conclusions:

  • Updated guidelines emphasize weight-based heparin dosing and extended oral anticoagulation duration.
  • Low-molecular-weight heparins provide a convenient and effective alternative for treatment and prophylaxis.
  • Adherence to these revised protocols can improve DVT management and patient outcomes.